PRAX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

59.44K

-80.32%

-3.093

+5.21%

-3.306

+0.47%

-3.414

+3.16%

Estimates Revision

The market is revising Downward the revenue expectations for Praxis Precision Medicines, Inc. (PRAX) for FY2025, with the revenue forecasts being adjusted by -18.84% over the past three months. During the same period, the stock price has changed by 442.24%.

Revenue Estimates for FY2025

Revise Downward

-18.84%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-3.31%

In Past 3 Month

Stock Price

Go Up

+442.24%

In Past 3 Month

14 Analyst Rating

Wall Street analysts forecast PRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRAX is 327.08 USD with a low forecast of 250.00 USD and a high forecast of 540.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

250.00

Averages

327.08

High

540.00

Current: 0.000

Low

250.00

Averages

327.08

High

540.00

Needham

Ami Fadia

Buy

upgrade

$315 -> $460

2026-01-05

New

Reason

Needham

Ami Fadia

Price Target

$315 -> $460

2026-01-05

New

upgrade

Buy

Reason

Needham analyst Ami Fadia raised the firm's price target on Praxis Precision to $460 from $315 and keeps a Buy rating on the shares. The firm sees 2026 as an extension of 2025 for the stock, with multiple new drug application submissions. Praxis could also win approval for ulixacaltamide in essential tremor, if given priority review, based on the unmet need, the analyst tells investors in a research note. Needham sees positive momentum for Praxis in 2026 based on potential approval and multiple data catalysts.

Jefferies

Andrew Tsai

70% -> 80%-90%

upgrade

$450

2025-12-29

Reason

Jefferies

Andrew Tsai

Price Target

$450

2025-12-29

upgrade

70% -> 80%-90%

Reason

After Praxis Precision Medicines announced that the FDA has granted Breakthrough Therapy Designation for ulixacaltamide for the treatment of patients with essential tremor, Jefferies analyst Andrew Tsai calls the news "fundamentally de-risking" as well as "notable FDA validation" since it can be inferred that the FDA has vetted the data package that includes two positive Phase 3 studies. The firm, which notes that programs receiving BTD have a high 73% approval rate, raises its view of the odds off success of ulixacaltamide in essential tremor to 80%-90% from 70% previously. Jefferies has a Buy rating and $450 price target on Praxis shares.

BTIG

Buy

upgrade

$507 -> $843

2025-12-29

Reason

BTIG

Price Target

$507 -> $843

2025-12-29

upgrade

Buy

Reason

BTIG raised the firm's price target on Praxis Precision to $843 from $507 and keeps a Buy rating on the shares. The firm views the company's launch of ulixacaltamide is "uniquely advantaged," saying Praxis will build an "unprecedented" 1M essential tremor patient database that should translate into rapid uptake. BTIG increased its net U.S. price for ulixacaltamide to $36,000 from $14,000, citing its favorable pricing analogue analysis. The firm views its assumptions as conservative given management's messaging indicating higher pricing. The market for VMAT2 inhibitors in tardive dyskinesia represents a good analogue for ulixacaltamide in essential tremors, but the latter will be a larger, less competitive, and commercially more attractive opportunity, the analyst tells investors in a research note. BTIG thinks Praxis has a "strong 2026 catalyst path." It names the stock a top pick for 2026.

Oppenheimer

Outperform

maintain

$250 -> $750

2025-12-15

Reason

Oppenheimer

Price Target

$250 -> $750

2025-12-15

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Praxis Precision to $750 from $250 and keeps an Outperform rating on the shares. The firm sees substantial momentum building for Praxis as recent clinical and regulatory updates derisk large commercial opportunities that it believes remain undervalued. Praxis now plans an NDA filing in early 2026 for relutrigine in SCN2A/8A patients following FDA discussions, enabling approval and launch in 2027. Oppenheimer believes the positive Phase 2/3 EMBOLD study and critical need for treatment support accelerated uptake and a high value proposition to payors.

Deutsche Bank

Buy

maintain

$303 -> $313

2025-12-12

Reason

Deutsche Bank

Price Target

$303 -> $313

2025-12-12

maintain

Buy

Reason

Deutsche Bank raised the firm's price target on Praxis Precision to $313 from $303 and keeps a Buy rating on the shares. The firm sees a "clear path" to a new drug application filing for relutrigine.

Jefferies

Buy

maintain

$300 -> $450

2025-12-09

Reason

Jefferies

Price Target

$300 -> $450

2025-12-09

maintain

Buy

Reason

Jefferies raised the firm's price target on Praxis Precision to $450 from $300 and keeps a Buy rating on the shares. Praxis Precision could file two NDAs in early 2026 following positive pivotal EMBOLD's Cohort 2 interim data for relutrigine in SCN2A/8A and a positive pre-NDA outcome for ulixacaltamide in ET essential tremor, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Praxis Precision Medicines Inc (PRAX.O) is -21.34, compared to its 5-year average forward P/E of -4.53. For a more detailed relative valuation and DCF analysis to assess Praxis Precision Medicines Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.53

Current PE

-21.34

Overvalued PE

-0.59

Undervalued PE

-8.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.99

Current EV/EBITDA

-20.94

Overvalued EV/EBITDA

0.92

Undervalued EV/EBITDA

-6.91

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

674.71

Current PS

8230.35

Overvalued PS

2094.87

Undervalued PS

-745.44

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PRAX News & Events

Events Timeline

No data

News

5.0

01-08Globenewswire

Praxis Appoints New Board Members and Promotes Executives to Enhance Growth Strategy

8.5

01-07Benzinga

Bright Minds Biosciences Launches $100 Million Public Offering

8.5

01-07Yahoo Finance

Praxis Precision Medicines Prices Underwritten Public Offering, Amount Undisclosed

People Also Watch

Frequently Asked Questions

What is Praxis Precision Medicines Inc (PRAX) stock price today?

The current price of PRAX is 294.38 USD — it has increased 0.6 % in the last trading day.

What is Praxis Precision Medicines Inc (PRAX)'s business?

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.

What is the price predicton of PRAX Stock?

What is Praxis Precision Medicines Inc (PRAX)'s revenue for the last quarter?

Praxis Precision Medicines Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What is Praxis Precision Medicines Inc (PRAX)'s earnings per share (EPS) for the last quarter?

Praxis Precision Medicines Inc. EPS for the last quarter amounts to -3.36 USD, increased 22.18 % YoY.

What changes have occurred in the market's expectations for Praxis Precision Medicines Inc (PRAX)'s fundamentals?

How many employees does Praxis Precision Medicines Inc (PRAX). have?

Praxis Precision Medicines Inc (PRAX) has 116 emplpoyees as of January 09 2026.

What is Praxis Precision Medicines Inc (PRAX) market cap?

Today PRAX has the market capitalization of 7.42B USD.